Literature DB >> 9563568

Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders.

M G van Oijen1, G Rijksen, F W ten Broek, P J Slootweg.   

Abstract

To examine which proteins are responsible for the elevated protein tyrosine kinase (PTK) activity in human head and neck squamous cell carcinoma (HNSCC) and adjacent histologically normal epithelium, paraffin embedded sections of these tissues were stained for PTK c-Src. Using double labeling techniques and antibodies against both the proliferation marker Ki-67 and PTK c-Src, we have shown that c-Src is overexpressed in areas of hyperproliferation in HNSCC, dysplastic epithelium, benign papillomas and inflamed normal tissue. Our data indicate that c-Src is (one of) the protein(s) responsible for the increased PTK activity in HNSCC. We could not demonstrate that c-Src expression is responsible for the increased PTK activity in normal epithelium adjacent to tumour tissue. We assume that c-Src plays a role in the increased proliferation seen in (pre)malignant and benign epithelial lesions as well as in reactive inflammatory epithelial hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563568     DOI: 10.1111/j.1600-0714.1998.tb01931.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  14 in total

1.  Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Authors:  Matthew G Fury; Shrujal Baxi; Ronglai Shen; Katherine W Kelly; Brynna L Lipson; Diane Carlson; Hilda Stambuk; Sofia Haque; David G Pfister
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

2.  Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.

Authors:  Amanda Gatesman Ammer; Laura C Kelley; Karen E Hayes; Jason V Evans; Lesly Ann Lopez-Skinner; Karen H Martin; Barbara Frederick; Brian L Rothschild; David Raben; Paul Elvin; Tim P Green; Scott A Weed
Journal:  J Cancer Sci Ther       Date:  2009-11-30

3.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion.

Authors:  Hiroshi Nozawa; Gina Howell; Shinsuke Suzuki; Qing Zhang; Yanjun Qi; Judith Klein-Seetharaman; Alan Wells; Jennifer R Grandis; Sufi M Thomas
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

5.  Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity.

Authors:  Kyung Mi Lee; Ki Won Lee; Sung Keun Jung; Eun Jung Lee; Yong-Seok Heo; Ann M Bode; Ronald A Lubet; Hyong Joo Lee; Zigang Dong
Journal:  Biochem Pharmacol       Date:  2010-07-01       Impact factor: 5.858

Review 6.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

Review 7.  Src family kinases and paclitaxel sensitivity.

Authors:  Xiao-Feng Le; Robert C Bast
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

Review 8.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

9.  Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.

Authors:  Banibrata Sen; Babita Saigal; Nila Parikh; Gary Gallick; Faye M Johnson
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

10.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.